HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

tibolone

used in prevention of postmenopausal osteoporosis

Also Known As:

Berenguer Infale brand of tibolone; Boltin; Livial; Liviella; Org OD 14; Org OD14; Organon brand of tibolone; tibilone; 19-Norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7-alpha,17-alpha)-

Networked: 387 relevant articles (55 outcomes, 120 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 56
- Steroids: 18537
  - Norsteroids: 12
    - Norpregnanes: 1
      - Norpregnenes
        tibolone: 387

Experts

1.	Kloosterboer, H J: 11 articles (05/2007 - 09/2000)
2.	Kloosterboer, Helenius J: 8 articles (12/2011 - 02/2004)
3.	Clarkson, Thomas B: 8 articles (07/2008 - 01/2002)
4.	Helmond, Frans A: 6 articles (10/2007 - 12/2003)
5.	Mol-Arts, Mirjam: 5 articles (01/2012 - 08/2008)
6.	Kenemans, Peter: 5 articles (01/2012 - 08/2008)
7.	Foidart, Jean-Michel: 4 articles (01/2012 - 01/2007)
8.	Kubista, Ernst: 4 articles (01/2012 - 07/2007)
9.	Nijland, E A: 4 articles (04/2009 - 10/2007)
10.	Seeger, H: 4 articles (10/2008 - 11/2001)

Related Diseases

1.	Osteoporosis 08/30/2004 - "In conclusion, the results suggest that tibolone is a cardiovascular-safe treatment that is effective for the prevention of osteoporosis and that may have advantages over CEE or CEE + MPA with regard to endometrial and breast safety." 05/01/2004 - "Tibolone possesses estrogenic activity and is effective for treating the symptoms and osteoporosis associated with menopause. " 01/01/2003 - "Tibolone is a synthetic steroid effective for the treatment of climacteric symptoms and osteoporosis. " 06/01/1991 - "This study was conducted to evaluate the efficacy of a daily oral dose of 2.5 mg Org OD 14 ((7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one) in the treatment of established osteoporosis. " 03/01/2009 - "This Practice Point commentary discusses a double-blind, placebo-controlled trial by Cummings et al. that investigated the effects of tibolone 1.25 mg per day in 4,534 postmenopausal women (mean age 68 years) with osteoporosis. "
2.	Hemorrhage 01/01/2012 - "When compared to equipotent doses of combined HT, tibolone reduced vaginal bleeding (15 RCTs, n = 6342; OR 0.32, 95% CI 0.24 to 0.42) but was less effective in relieving the frequency of vasomotor symptoms (two RCTs, n = 545; OR 4.16, 95% CI 1.50 to 11.58).As for long term safety, two major RCTs of tibolone versus placebo provided the most relevant data. " 01/01/2012 - "When compared to placebo, tibolone was more effective in relieving the frequency of vasomotor symptoms (two RCTs, n = 847; OR 0.42, 95% CI 0.25 to 0.69), although only the 2.5 mg/day dose of tibolone was significantly better than placebo; but with increased vaginal bleeding (seven RCTs, n = 7462; OR 2.75, 95% CI 1.99 to 3.80). " 08/01/2002 - "Treatment with tibolone led to a significantly lower bleeding rate during cycles 4-6 compared with CEE-MPA (15.0% vs 26.9%; P = 0.004); there was a similar difference during cycles 1-3. Both treatments improved QoL, wellbeing, climacteric symptoms and urogenital complaints. " 03/01/2002 - "Women treated with CEE/MPA or tibolone showed significant improvement of postmenopausal symptoms, including urogenital and sexual health symptoms, and had similar bleeding patterns after four cycles of therapy. " 08/01/2010 - "Recent studies show that, in comparison to HRT, tibolone is as effective in alleviating menopausal symptoms and preventing bone loss, has a greater positive effect on sexual dysfunction and is associated with less vaginal bleeding, but it is rarely mentioned in guidelines for menopausal treatment. "
3.	Breast Neoplasms (Breast Cancer) 12/01/2011 - "The results of the LIBERATE trial show that tibolone is effective in symptomatic breast cancer patients and improves their quality of life. " 12/01/2011 - "Tibolone, a synthetic steroid, is effective in reducing these symptoms in healthy post-menopausal women, but this has never been studied in a large breast cancer population. " 12/01/2005 - "Tibolone was effective in the treatment of climacteric symptoms and well tolerated in a group of 52 women with a history of breast cancer. " 10/01/2006 - "On the other hand, although epidemiological studies show an increase in the risk of breast cancer among women treated with tibolone, accumulation of data obtained from radiological studies presents promising results. " 02/01/2009 - "Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial."
4.	Atrophy 06/01/2012 - "The improvement in blood biochemistry, endometrial atrophy and maintenance of the anthropometrical measures reflected the safety of Tibolone use. " 11/01/2006 - "To demonstrate the safety and efficacy of tibolone (1.25 and 2.5 mg) in the treatment of moderate to severe vasomotor symptoms and symptoms associated with vaginal atrophy. " 11/01/2006 - "Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study." 08/01/2011 - "Tibolone administered in high dose and for a long period has a trophic effect, reversing vaginal atrophy, and has no dysplastic or neoplastic effect in the vagina of ovariectomized rats." 11/01/2006 - "Tibolone is effective and well tolerated for the treatment of moderate to severe vasomotor symptoms and the effects of vaginal atrophy associated with menopause."
5.	Myoma 01/01/2002 - "Triptoreline is a GnRHa which has been found to be effective in reducing myoma volume, but this effect could not be deactivated with tibolone. " 01/01/2000 - "Tibolone seems a valid alternative in menopausal patients with uterine myomas as it provides adequate relief from menopausal symptoms and avoids volume increase of the uterus and myomas." 01/01/2014 - "The median myoma volume decreased upon iCR by as much as -30% (P = 0.016) but increased upon tibolone by +4.7%. " 07/25/2002 - "There are no statistical significant differences between tibolone and transdermal hormonal replacement therapy regimens in respect to increase in the size of myoma uteri." 01/01/2002 - "The effects of add-back therapy with tibolone on myoma uteri."

Related Drugs and Biologics

1.	tibolone
2.	Estrogens (Estrogen)
3.	Conjugated (USP) Estrogens (Premarin)
4.	Tamoxifen
5.	Cholesterol
6.	Raloxifene (Evista)
7.	Medroxyprogesterone Acetate (Depo-Provera)
8.	Estradiol (Estrace)
9.	Hormones
10.	Gonadotropin-Releasing Hormone (GnRH)

Related Therapies and Procedures

1.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
2.	Ovariectomy (Oophorectomy)
3.	Hysterectomy
4.	Estrogen Replacement Therapy
5.	Aftercare (After-Treatment)